Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MVCD4
MCID: MCR133
MIFTS: 41

Microvascular Complications of Diabetes 4 (MVCD4)

Categories: Cardiovascular diseases, Eye diseases, Genetic diseases, Nephrological diseases, Neuronal diseases
Genes Variations Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Microvascular Complications of Diabetes 4

About this section

MalaCards integrated aliases for Microvascular Complications of Diabetes 4:

Name: Microvascular Complications of Diabetes 4 57 72 29 13 6 39
Diabetic Nephropathy 72 70
Mvcd4 57 72
Microvascular Complications of Diabetes, Susceptibility to, 4 57
Nephropathy, Diabetic, Susceptibility to 57
Nephropathy, Diabetic 57

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Nephrological diseases Eye diseases Cardiovascular diseases Neuronal diseases
See all MalaCards categories (disease lists)


External Ids:

OMIM® 57 612628
OMIM Phenotypic Series 57 PS603933
MeSH 44 D048909
UMLS 70 C0011881
Sources

Summaries for Microvascular Complications of Diabetes 4

About this section
UniProtKB/Swiss-Prot : 72 Microvascular complications of diabetes 4: Pathological conditions that develop in numerous tissues and organs as a consequence of diabetes mellitus. They include diabetic retinopathy, diabetic nephropathy leading to end-stage renal disease, and diabetic neuropathy. Diabetic retinopathy remains the major cause of new-onset blindness among diabetic adults. It is characterized by vascular permeability and increased tissue ischemia and angiogenesis.

MalaCards based summary : Microvascular Complications of Diabetes 4, also known as diabetic nephropathy, is related to microvascular complications of diabetes 1 and microvascular complications of diabetes 2. An important gene associated with Microvascular Complications of Diabetes 4 is IL1RN (Interleukin 1 Receptor Antagonist). The drugs Clopidogrel and Zaleplon have been mentioned in the context of this disorder. Affiliated tissues include kidney, endothelial and pancreas.

More information from OMIM: 612628 PS603933
Sources

Related Diseases for Microvascular Complications of Diabetes 4

About this section

Diseases in the Microvascular Complications of Diabetes 1 family:

Microvascular Complications of Diabetes 2 Microvascular Complications of Diabetes 3
Microvascular Complications of Diabetes 4 Microvascular Complications of Diabetes 5
Microvascular Complications of Diabetes 6 Microvascular Complications of Diabetes 7

Diseases related to Microvascular Complications of Diabetes 4 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 425)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 11.5
2 microvascular complications of diabetes 2 11.5
3 type 1 diabetes mellitus 11.4
4 microvascular complications of diabetes 3 11.3
5 microvascular complications of diabetes 6 11.3
6 microvascular complications of diabetes 7 11.3
7 diabetic angiopathy 11.1
8 maturity-onset diabetes of the young 11.1
9 hyperglycemia 11.1
10 renal fibrosis 11.0
11 type 2 diabetes mellitus 11.0
12 diabetes mellitus 11.0
13 fibrosis of extraocular muscles, congenital, 1 10.9
14 chronic kidney disease 10.9
15 glomerulonephritis 10.8
16 lipid metabolism disorder 10.8
17 nephrotic syndrome 10.7
18 vascular disease 10.7
19 uremia 10.6
20 hypertension, essential 10.6
21 iga glomerulonephritis 10.6
22 membranous nephropathy 10.5
23 neuropathy 10.5
24 peripheral vascular disease 10.5
25 arteriosclerosis 10.5
26 glomerular disease 10.5
27 kidney hypertrophy 10.5
28 autonomic neuropathy 10.5
29 hyperinsulinism 10.4
30 diabetic neuropathy 10.4
31 pre-eclampsia 10.4
32 nephrosclerosis 10.4
33 hypoglycemia 10.4
34 cytokine deficiency 10.4
35 hypercholesterolemia, familial, 1 10.4
36 hyperuricemia 10.4
37 rickets 10.4
38 congestive heart failure 10.4
39 hypertriglyceridemia, familial 10.4
40 proteasome-associated autoinflammatory syndrome 1 10.4
41 acute kidney failure 10.4
42 yemenite deaf-blind hypopigmentation syndrome 10.4
43 muscle hypertrophy 10.4
44 glucose intolerance 10.4
45 peripheral nervous system disease 10.4
46 hypoxia 10.4
47 arteries, anomalies of 10.4
48 atherosclerosis susceptibility 10.4
49 lipoprotein quantitative trait locus 10.4
50 deficiency anemia 10.4

Graphical network of the top 20 diseases related to Microvascular Complications of Diabetes 4:



Diseases related to Microvascular Complications of Diabetes 4
Sources

Symptoms & Phenotypes for Microvascular Complications of Diabetes 4

About this section

Clinical features from OMIM®:

612628 (Updated 05-Apr-2021)

Sources

Drugs & Therapeutics for Microvascular Complications of Diabetes 4

About this section

Drugs for Microvascular Complications of Diabetes 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 231)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
2
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
3
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
4
Enalaprilat Approved Phase 4 76420-72-9 6917719
5
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
6
Doxazosin Approved Phase 4 74191-85-8 3157
7
Simvastatin Approved Phase 4 79902-63-9 54454
8
Ramipril Approved Phase 4 87333-19-5 5362129
9
Liraglutide Approved Phase 4 204656-20-2 44147092
10
Insulin glargine Approved Phase 4 160337-95-1
11
Insulin glulisine Approved Phase 4 207748-29-6
12
carbamide peroxide Approved Phase 4 124-43-6
13
Probucol Approved, Investigational Phase 4 23288-49-5 4912
14
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
15
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
16
Nisoldipine Approved Phase 4 63675-72-9 4499
17
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
18
Atorvastatin Approved Phase 4 134523-00-5 60823
19
Indapamide Approved Phase 4 26807-65-8 3702
20
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
21
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
22
Amlodipine Approved Phase 4 88150-42-9 2162
23
Clonidine Approved Phase 4 4205-90-7 2803
24
Atenolol Approved Phase 4 29122-68-7 2249
25
Trandolapril Approved Phase 4 87679-37-6 5484727
26
Verapamil Approved Phase 4 52-53-9 2520
27
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124
28
Saxagliptin Approved Phase 4 361442-04-8 11243969
29
Insulin lispro Approved Phase 4 133107-64-9
30
Metformin Approved Phase 4 657-24-9 4091 14219
31
Captopril Approved Phase 4 62571-86-2 44093
32
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
33
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
34
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
35
Niclosamide Approved, Investigational, Vet_approved Phase 4 50-65-7 4477
36
Lisinopril Approved, Investigational Phase 4 83915-83-7, 76547-98-3 5362119
37
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
38
Losartan Approved Phase 4 114798-26-4 3961
39
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 70-16-6, 59-43-8 1130
40
Alfacalcidol Approved, Nutraceutical Phase 4 41294-56-8 5282181
41
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
42
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
43
Sarpogrelate Investigational Phase 4 125926-17-2 5160
44
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
45
Candesartan Experimental Phase 4 139481-59-7 2541
46 Purinergic P2Y Receptor Antagonists Phase 4
47 Thiamin Phase 4
48 diuretics Phase 4
49 Neurotransmitter Agents Phase 4
50 Adrenergic alpha-1 Receptor Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 250)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized, Two Period, With an Intermediate Wash Out Period, Cross-over Study to Compare the Effects of Either Combined Therapy With Ramipril and Clopidogrel or Ramipril Monotherapy on Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Patients With Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
2 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
3 Effect of Intravenous and Oral Therapy With Sulodexide on Albuminuria in Type 2 Diabetic Patients Unknown status NCT01316068 Phase 4 intravenous use of sulodexide followed by oral use;use of sulodexide orally only
4 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
5 Phase 4 Study of Mechanisms of Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
6 Effect of Aldosterone Antagonism in the Reduction of Albuminuria and Diastolic Disfunction of Patients With Diabetic Nephropathy. Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
7 Prevention of Renal Complications of Diabetes With Thiamine Unknown status NCT01725412 Phase 4
8 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Nephropathy Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
9 Antiproteinuric Effect of Valsartan, Lisinopril and Valsartan Plus Lisinopril in Non-diabetic and Diabetic Renal Disease: a Randomized, Double Blind, Parallel Group, Controlled Trial With 5 Months Follow-up Completed NCT00171574 Phase 4 Valsartan;Valsartan plus HCTZ;Lisinopril
10 Effect of Enalapril and Losartan Association Therapy on Proteinuria and Inflammatory Biomarkers in Diabetic Nephropathy: a Clinical Trial on Type 2 Diabetes Mellitus Completed NCT00419835 Phase 4 enalapril;losartan
11 Effects of Doxazosin on Ambulatory Blood Pressure and Sympathetic Nervous Activity in Hypertensive Patients With Diabetic Nephropathy Completed NCT00295555 Phase 4 Effects of doxazosin on morning surge in diabetic patients
12 Effect of Renin Angiotensin System Blockade on CD95 and ADMA Levels in Type-2 Diabetic Patients With Proteinuria Completed NCT00893425 Phase 4 ramipril
13 A Randomised, Double-blinded, Cross-over Study Investigating the Short-term Impact of Liraglutide on Kidney Function in Diabetic Patients Completed NCT01664676 Phase 4 Liraglutide;Placebo-liraglutide
14 A Randomised, Double-blind, Placebo-controlled, Multicenter Trial to Investigate the Preventive Effect of BIBR277 (Telmisartan) in Diabetic Nephropathy on Transition From Incipient to Overt Nephropathy - Incipient to Overt : Angiotensin 2 Receptor Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION Study - Completed NCT00153088 Phase 4 Telmisartan capsule 40 mg;Placebo;Telmisartan capsule 80 mg
15 Combined Diabetes-Renal Multifactorial Intervention In Patients With Advanced Diabetic Nephropathy (ADN) Completed NCT00708981 Phase 4
16 Spironolactone in Diabetic Nephropathy Completed NCT00317954 Phase 4 Spironolactone
17 A Prospective, Multi-center, Randomized, Open-label, Parallel-arm Controlled Study of Treating Type 2 Diabetic Nephropathy (Stage II-IV) With Alfacalcidol and Irbesartan Completed NCT03147677 Phase 4 Alfacalcidol;Irbesartan
18 A Multicenter, Randomized, Open-label, Parallel-group, Diabetic Diet-controlled Study to Evaluate the Efficacy and Safety of Compound α-Keto Acid Tablet in Combination With LPD in Delaying the Progress of Type 2 Diabetic Nephropathy Completed NCT00363987 Phase 4 Ketosteril®
19 A Randomized, Control, Parallel, Open Label, Multi-centre Clinical Study to Evaluate the Efficacy and Safety of Cilostazol and Probucol in Combination on Patients With Diabetic Nephropathy Completed NCT01252056 Phase 4 Probucol;Probucol and Cilostazol
20 Renoprotective Effect of Nisoldipine and Lisinopril in Type 1 Diabetic Nephropathy Completed NCT00311870 Phase 4 nisoldipine;lisinopril
21 A 28-week, Randomised, Open-label, Parallel-Group, Multi-Center Study To Find the Effective Dose of Candesartan Cilexetil (Atacand) for Renoprotection in Korean Hypertensive Patients With Non-diabetic Nephropathy Completed NCT00573430 Phase 4 Candesartan Cilexetil;Candesartan Cilexetil;Candesartan Cilexetil 32mg
22 A Double-Blind Clinical Trial of Benfotiamine Treatment in Diabetic Nephropathy Completed NCT00565318 Phase 4 Benfotiamine;Placebo
23 Renal Denervation in Patients With Diabetic Nephropathy and Persistent Proteinuria Completed NCT01588795 Phase 4 Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin
24 Lipo-prostaglandin E1 Improves Renal Hypoxia Evaluated by BOLD-MRI in Patients Completed NCT02628106 Phase 4 Lipo-PGE1
25 "Safety and Efficacy of Acthar Gel on Albuminuria and Urinary Transforming Growth Factor Excretion in Type I or Type II Diabetics Requiring Medical Treatment of Hyperglycemia With Nephrotic Range Proteinuria: A Pilot Study" Completed NCT01028287 Phase 4 ACTH;ACTH
26 Nephropathy in Type 2 Diabetes: Effects of an Intensive Multifactorial Intervention Trial on Cardio-renal Events. Completed NCT00535925 Phase 4 SoC therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
27 A Single Arm Open Label Multicenter Interventional Study to Assess the Efficacy, Safety, and Tolerability of Every 4 Weeks Administration of Subcutaneous C.E.R.A. for the Treatment of Chronic Renal Anemia in Diabetic Nephropathy With Chronic Kidney Disease Stages III-IV Not on Dialysis, Not Currently Treated With ESA. Completed NCT01191983 Phase 4 Methoxy polyethylene glycol-epoetin beta [Mircera]
28 A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy Completed NCT00234871 Phase 4 trandolapril/verapamil;Lotrel (amlodipine/benazepril)
29 Effects of Atorvastatin Versus Probucol on Low-Density Lipoprotein Subtype Distribution and Renal Function in Hyperlipidemic Patients With Non-Diabetic Nephropathy Completed NCT00276133 Phase 4 Effects of atorvastatin versus probucol on small dense LDL
30 A Randomised, Double-Blind, Placebo-Controlled Study of Cilostazol 100 mg Twice Daily in the Treatment of Diabetic Nephropathy in Hong Kong Chinese Completed NCT00272831 Phase 4 Cilostazol;Placebo
31 A Two-Phase Study for Primary and Secondary Prevention of Diabetic Nephropathy by Combined ACE Inhibition and Calcium Channel Blockade (BENEDICT) Completed NCT00235014 Phase 4 trandolapril;trandolapril/verapamil;placebo;verapamil
32 A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Patients With Diabetic Nephropathy Completed NCT04521049 Phase 4 Saxagliptin 5mg
33 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy: a 24- Week Study Completed NCT02690883 Phase 4 Exenatide;Lispro
34 The Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic Nephropathy Completed NCT01331317 Phase 4 Paricalcitol
35 Comparative Effects of add-on Pentoxifylline to Losartan Versus Increasing Dose of Losartan on Serum NT-PRO BNP and Proteinuria in Type 2 Diabetics With Nephropathy Completed NCT03006952 Phase 4 Pentoxifylline;Losartan
36 A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Investigate the Efficacy of Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy VIVALDI-Study Completed NCT00153023 Phase 4 Telmisartan;Valsartan
37 Pentoxifylline Effect on Renal Function, Oxidative Stress, Inflammation, and Fibrosis Markers, and Quality of Life in Patients With Diabetic Nephropathy Recruiting NCT03664414 Phase 4 pentoxifylline
38 Comparative Effecacy of Metformin and Vildagliptin on Cardiometabolic Risk Factors, Metabolic Syndrome, and Diabetic Nephropathy Progression Recruiting NCT04485845 Phase 4 Vildagliptin;Captopril Tablets;MetFORMIN 500 Mg Oral Tablet
39 Effect of SGLT2 Inhibitor on Proteinuria in Diabetic Patients Recruiting NCT03573102 Phase 4 SGLT2 inhibitor;ACE inhibitor
40 Possible Role of Niclosamide in Patients With Diabetic Kidney Disease: Randomized Controlled Study Recruiting NCT04317430 Phase 4 Niclosamide;Placebo oral tablet
41 Effect of Continuous Positive Airway Pressure on Albuminuria in Patients With Diabetic Nephropathy and Obstructive Sleep Apnea Active, not recruiting NCT02816762 Phase 4 Pharmacological treatment
42 Comparative, Open Multicenter Trial Assessing the Effect on Albumin Excretion Rate of 320mg Valsartan (With or Without HCTZ) vs 40mg Lisinopril (With or Without HCTZ) on Hypertensive Patients With Diabetic and Non-diabetic Nephropathy and Albuminuria Terminated NCT00171600 Phase 4 VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ
43 The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy Terminated NCT00130312 Phase 4 Sulodexide;Placebo
44 Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation: A Rotation Study of Different Albuminuria Lowering Drug Classes to Study Individual Drug Response in Diabetes Withdrawn NCT03504566 Phase 4 Linagliptin;Empagliflozin;Telmisartan;Sulodexide
45 International, Multicenter, Prospective, Randomized, Parallel Group, Open Label Protocol to Evaluate Safety and Efficacy of Isolated Pancreas Transplantation Compared to Intensive Insulin Therapy in Type 1 Diabetic Patients With Overt Diabetic Nephropathy and Mildly Reduced Renal Function Unknown status NCT01067950 Phase 3 Intensive Insulin Therapy
46 Interaction of Polymorphism rs35652124 With Curcumin Supplementation on NFE2L2 Gene Expression, Antioxidant Capacity and Renal Function in Patients With Early Diabetic Nephropathy Unknown status NCT03262363 Phase 2, Phase 3
47 Intervention Using Vitamin D for Elevated Urinary ALbumin in Diabetes (IDEAL-2) Unknown status NCT03216564 Phase 3 Calcitriol
48 CS-866DM Phase 3 Clinical Study: A Double-Blind Controlled Trial in Patients With Diabetic Nephropathy and Overt Proteinuria Secondary to Type 2 Diabetes Mellitus Completed NCT00141453 Phase 3 olmesartan medoxomil;Placebo Tablets
49 Resistant Hypertension in Patient With Diabetic Nephropathy: Role of Sleep Apnea and Associated Sympathetic Hyperactivity. Completed NCT01875341 Phase 3
50 Randomized Study of Antihypertensives and Antilipemics in American Indians With Non-Insulin-Dependent Diabetes Mellitus at High Risk of Developing Nephropathy and Cardiovascular Disease Completed NCT00004266 Phase 3 Lisinopril;Nifedipine;Simvastatin

Search NIH Clinical Center for Microvascular Complications of Diabetes 4

Inferred drug relations via UMLS 70 / NDF-RT 51 :


benazepril
Benazepril hydrochloride
candesartan
candesartan cilexetil
Captopril
Enalapril
Enalapril Maleate
Enalaprilat
eprosartan
Eprosartan mesylate
Fosinopril
Fosinopril Sodium
irbesartan
Lisinopril
Losartan
Losartan Potassium
moexipril
Moexipril hydrochloride
olmesartan
Olmesartan medoxomil
Perindopril
Perindopril arginine
Perindopril Erbumine
quinapril
Quinapril hydrochloride
Ramipril
telmisartan
trandolapril
valsartan
Sources

Genetic Tests for Microvascular Complications of Diabetes 4

About this section

Genetic tests related to Microvascular Complications of Diabetes 4:

# Genetic test Affiliating Genes
1 Microvascular Complications of Diabetes 4 29 IL1RN
Sources

Anatomical Context for Microvascular Complications of Diabetes 4

About this section

MalaCards organs/tissues related to Microvascular Complications of Diabetes 4:

40
Kidney, Endothelial, Pancreas, Cortex, Neutrophil, Skin, Bone Marrow
Sources

Publications for Microvascular Complications of Diabetes 4

About this section

Articles related to Microvascular Complications of Diabetes 4:

(show top 50) (show all 19005)
# Title Authors PMID Year
1
Polymorphisms in interleukin-1 beta and Interleukin-1 receptor antagonist genes are associated with kidney failure in Korean patients with type 2 diabetes mellitus. 61 6 57
15286433 2004
2
Interleukin-1 receptor antagonist allele (IL1RN*2) associated with nephropathy in diabetes mellitus. 57 6 61
8786086 1996
3
Interleukin-1 system gene polymorphisms are associated with fat mass in young men. 6
16636119 2006
4
Osteoporotic fractures are associated with an 86-base pair repeat polymorphism in the interleukin-1--receptor antagonist gene but not with polymorphisms in the interleukin-1beta gene. 6
10750554 2000
5
Interleukin-1 polymorphisms associated with increased risk of gastric cancer. 6
10746728 2000
6
Association of interleukin-1beta and interleukin-1 receptor antagonist genes with disease severity in MS. 6
10025794 1999
7
Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. 6
8500797 1993
8
Urinary calprotectin, NGAL, and KIM-1 in the differentiation of primarily inflammatory vs. non-inflammatory stable chronic kidney diseases. 61
33663323 2021
9
Yishen capsule promotes podocyte autophagy through regulating SIRT1/NF-κB signaling pathway to improve diabetic nephropathy. 61
33427556 2021
10
The predictive value of diabetic retinopathy on subsequent diabetic nephropathy in patients with type 2 diabetes: a systematic review and meta-analysis of prospective studies. 61
33478336 2021
11
Medium-term outcomes of multi-disciplinary surgical management of non-ischemic diabetic heel ulcers. 61
33717969 2021
12
Post-operative gastroparesis following carbohydrate loading in a diabetic patient. 61
33644283 2021
13
Increased lipoxygenase and decreased cytochrome P450s metabolites correlated with the incidence of diabetic nephropathy: Potential role of eicosanoids from metabolomics in type 2 diabetic patients. 61
33605471 2021
14
Loganin alleviates macrophage infiltration and activation by inhibiting the MCP-1/CCR2 axis in diabetic nephropathy. 61
33245967 2021
15
An updated pharmacological insight of resveratrol in the treatment of diabetic nephropathy. 61
33631244 2021
16
Curcumin analogue C66 attenuates obesity-induced renal injury by inhibiting chronic inflammation. 61
33761621 2021
17
Therapeutic potential of curcumin in diabetic retinopathy (Review). 61
33693955 2021
18
Behavioral characterization of a novel Cisd2 mutant mouse. 61
33610659 2021
19
Acute glucose fluctuation promotes RAGE expression via reactive oxygen species‑mediated NF‑κB activation in rat podocytes. 61
33760170 2021
20
Piperazine ferulate attenuates high glucose‑induced mesangial cell injury via the regulation of p66Shc. 61
33760157 2021
21
The integrated study on the chemical profiling and in vivo course to explore the bioactive constituents and potential targets of Chinese classical formula Qingxin Lianzi Yin Decoction by UHPLC-MS and network pharmacology approaches. 61
33609729 2021
22
Association between the triglyceride-glucose index and diabetic nephropathy in patients with type 2 diabetes: A cross-sectional study. 61
33319507 2021
23
Downregulation of miR-17 suppresses TGF-β1-mediated renal fibrosis through targeting Smad7. 61
33797702 2021
24
MiR-32-5p knockdown inhibits epithelial to mesenchymal transition and renal fibrosis by targeting SMAD7 in diabetic nephropathy. 61
32959695 2021
25
PTPN14 deficiency alleviates podocyte injury through suppressing inflammation and fibrosis by targeting TRIP6 in diabetic nephropathy. 61
33684622 2021
26
Knockout of NGAL aggravates tubulointerstitial injury in a mouse model of diabetic nephropathy by enhancing oxidative stress and fibrosis. 61
33732294 2021
27
Nanomedicine in the treatment of diabetic nephropathy. 61
33677997 2021
28
Diphenyl diselenide ameliorates diabetic nephropathy in streptozotocin-induced diabetic rats via suppressing oxidative stress and inflammation. 61
33639173 2021
29
Correlation between serum carnosinase concentration and renal damage in diabetic nephropathy patients. 61
33811534 2021
30
Novel Linkage Peaks Discovered for Diabetic Nephropathy in Individuals With Type 1 Diabetes. 61
33414249 2021
31
CDK9 inhibition improves diabetic nephropathy by reducing inflammation in the kidneys. 61
33631230 2021
32
Pre-emptive Short-term Nicotinamide Mononucleotide Treatment in a Mouse Model of Diabetic Nephropathy. 61
33795425 2021
33
Multifunctional agents based on benzoxazolone as promising therapeutic drugs for diabetic nephropathy. 61
33588177 2021
34
Effect of genipin-1-β-d-gentiobioside on diabetic nephropathy in mice by activating AMP-activated protein kinase/silencing information regulator-related enzyme 1/ nuclear factor-κB pathway. 61
33792721 2021
35
FBXW7 mediates high glucose‑induced SREBP‑1 expression in renal tubular cells of diabetic nephropathy under PI3K/Akt pathway regulation. 61
33537812 2021
36
Antiangiogenic therapy in diabetic nephropathy: A double‑edged sword (Review). 61
33655322 2021
37
Network pharmacology combined with metabolomics to study the mechanism of Shenyan Kangfu Tablets in the treatment of diabetic nephropathy. 61
33444720 2021
38
Characterization of a novel polysaccharide from Moutan Cortex and its ameliorative effect on AGEs-induced diabetic nephropathy. 61
33581205 2021
39
An integrated network pharmacology and transcriptomic method to explore the mechanism of the total Rhizoma Coptidis alkaloids in improving diabetic nephropathy. 61
33444721 2021
40
Lipotoxicity dysregulates the immunoproteasome in podocytes and kidneys in type 2 diabetes. 61
33586497 2021
41
Combination therapy with Exendin-4 and islet transplantation as a synergistic treatment for diabetic nephropathy in rats. 61
33571517 2021
42
Silymarin nanoliposomes attenuate renal injury on diabetic nephropathy rats via co-suppressing TGF-β/Smad and JAK2/STAT3/SOCS1 pathway. 61
33577847 2021
43
Ginkgo biloba leaf extract prevents diabetic nephropathy through the suppression of tissue transglutaminase. 61
33732306 2021
44
Aptamer-functionalised magnetic particles for highly selective detection of urinary albumin in clinical samples of diabetic nephropathy and other kidney tract disease. 61
33736810 2021
45
Knockout of γ-Adducin Promotes NG-Nitro-L-Arginine-Methyl-Ester-Induced Hypertensive Renal Injury. 61
33414130 2021
46
Soluble α-klotho anchors TRPV5 to the distal tubular cell membrane independent of FGFR1 by binding TRPV5 and galectin-1 simultaneously. 61
33615893 2021
47
Diffusion-weighted imaging in the assessment of renal function in patients with diabetes mellitus type 2. 61
32734525 2021
48
MiR-1297 attenuates high glucose-induced injury in HK-2 cells via targeting COL1A2. 61
33811432 2021
49
Urinary adiponectin excretion is an early predictive marker of the decline of the renal function in patients with diabetes mellitus. 61
33558151 2021
50
Growth hormone induces mitotic catastrophe of glomerular podocytes and contributes to proteinuria. 61
33795655 2021
Sources

Variations for Microvascular Complications of Diabetes 4

About this section

ClinVar genetic disease variations for Microvascular Complications of Diabetes 4:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 IL1RN IL1RN, IVS2, 86-BP DUP Duplication risk factor 14674 GRCh37:
GRCh38:
Sources

Expression for Microvascular Complications of Diabetes 4

About this section
Search GEO for disease gene expression data for Microvascular Complications of Diabetes 4.
Sources

Pathways for Microvascular Complications of Diabetes 4

About this section
Sources

GO Terms for Microvascular Complications of Diabetes 4

About this section
Sources

Sources for Microvascular Complications of Diabetes 4

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....